Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Neoplasms 7Ovarian Neoplasms 6Colorectal Neoplasms 4Prostatic Neoplasms 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Recurrence 2Peritoneal Neoplasms 2Lung Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Radiation Pneumonitis 1Patients With Any Advanced Solid Tumors 1Ovarian Diseases 1Oligodendroglioma 1Neuroendocrine Tumors 1Neoplasms by Site 1Mesothelioma, Malignant 1Melanoma, Cutaneous Malignant 1Malignant Solid Tumour 1Lymphangioleiomyomatosis 1Leukemia, Myeloid, Acute 1

Interventions

Sunitinib 86Sorafenib 60Everolimus 47pazopanib 46Bevacizumab 46Nivolumab 44pembrolizumab 37aldesleukin 29Interferon-alpha 26Axitinib 24temsirolimus 23cabozantinib 20Interleukin-2 19Ipilimumab 16Interferon alpha-2 15Cyclophosphamide 15fludarabine phosphate 14Gemcitabine 14Peripheral Blood Stem Cell Transplantation 11Sirolimus 10Paclitaxel 10Erlotinib Hydrochloride 10avelumab 8Radiosurgery 8Docetaxel 8Cyclosporine 8Capecitabine 8tremelimumab 7lenvatinib 7Mycophenolic Acid 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Carcinoma, Renal Cell × nintedanib × Clear all
NCT01024920 2021-07-19

Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.

Boehringer Ingelheim

Phase 2 Completed
99 enrolled 45 charts
Genitourinary

Carcinoma, Renal Cell

NCT02835833 2018-07-10

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

University of Alabama at Birmingham

Phase 1 Completed
21 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡